SUNNYVALE, CA November 7, 2017 (PR NEWSWIRE)
ClearLight Diagnostics, LLC (ClearLight), a developer of a next generation tissue processing and 3D imaging platform for cancer tissue, announced today that it has licensed additional technology from Stanford University. The new license agreement provides exclusive intellectual property rights covering inventions that can be applied to CLARITY processed tissues, specifically for the visualization and quantification of immunolabeled long process structures such as tumor vasculature. Additional licensed inventions describe a flow-assisted tissue clearing device and a computational pipeline for automated image registration and quantification of cells in immunolabeled whole tissue samples imaged using light-sheet microscopy.
“ClearLight continues to build its portfolio of valuable CLARITY related technology through in-licensing as well as our own internal work.” said Sarah McCurdy, CEO of ClearLight. “The potential for our platform becomes stronger as we continually move forward with our internal product development program while enhancing our capabilities through the acquisition of additional, important IP.”
About ClearLight Diagnostics
ClearLight Diagnostics is a technology development company focused on the discovery, development, and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases with an initial focus in oncology.
Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing an integrated instrumentation platform with the associated optimized biomarker panels based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules.
Visit us at www.clearlightdx.com.
Sarah McCurdy, CEO